Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Burkitt Lymphoma 1

Interventions

tafasitamab 1Valganciclovir 1N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pyloric Stenosis, Hypertrophic × tafasitamab × Clear all
NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Xencor, Inc.

Phase 2 Terminated
3 enrolled 6 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡